Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Trigeminal Neuralgia. Safety Issues.
Sponsor: Norwegian University of Science and Technology
A PHASE1/PHASE2 clinical study on Headache Disorders and Trigeminal Neuralgia, this trial is completed. The trial is conducted by Norwegian University of Science and Technology and has accumulated 9 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Dec 2018 — Aug 2019 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
▶ Show 4 earlier versions
-
Jul 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Dec 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
May 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Norwegian University of Science and Technology
- St. Olavs Hospital
For direct contact, visit the study record on ClinicalTrials.gov .